Recruiting
Phase 2

COR-1167

Sponsor:

Corteria Pharmaceuticals

Code:

NCT06815471

Conditions

Worsening Heart Failure

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

COR-1167

Placebo

Study Details

Brief summary:

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Conditions

Worsening Heart Failure

Study ID

NCT06815471

Start date

Aug 7, 2025

Status verified date

Nov, 2026

Completion date

Jul, 2027

Anticipated

Primary completion date

Jul, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Signed written informed consent
  • Previous diagnosis of HF documented in source records and confirmed by investigator assessment (no historical written documentation required)
  • Prescribed an oral loop diuretic for at least 1 month preceding the index event
  • NT-proBNP ≥300 pg/mL or BNP ≥100 pg/mL
  • Requires treatment with i.v. diuretics for volume overload
  • At least 1 risk factor for diuretic resistance
  • Admitted to the hospital not more than 120 hours prior to randomization

Exclusion Criteria:

  • Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia)
  • Administration of i.v. inotropic therapy or i.v. vasodilators, use of mechanical ventilation, high-flow oxygen therapy, or NIV prior to randomization
  • Requirement for, or planned use of LVADs, IABP, or any type of MCS
  • History of solid organ transplant or active on a transplant list
  • SBP <100 mmHg
  • eGFR < 20 mL/min/1.73 m2
  • CABG, PCI, implantation of CRT, heart valve procedure or any cardiac surgery within 1 month prior to screening or planned during the study
  • Severe stenotic cardiac valvular disease
  • Severe chronic pulmonary disease requiring chronic steroid therapy or chronic oxygen therapy (> 2 L/min)
  • Uncorrected severe hyperthyroidism or hypothyroidism
  • Severe restrictive, obstructive, or infiltrative cardiomyopathy
  • Body weight < 70 kg at screening
  • Use of any investigational drug(s) within 5 half-lives of screening
  • At high risk of death, defined as life expectancy ≤1 year (such as participants in potential impending cardiogenic shock), or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult
  • Presence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures
  • Participant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
  • Increased lactate levels > upper limit of normal (local laboratory) at screening
  • Severe chronic liver disease (such as cirrhosis)

Study Design

Enrollment

210 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: COR-1167 low dose

placebo comparator: Placebo

Interventions

COR-1167

28-day treatment

Placebo

28-day treatment

Primary outcome measure

  • Natriuresis [ Time Frame: 24 hours ]
  • Body weight [ Time Frame: 7 days ]
  • NT-proBNP [ Time Frame: 7 days ]
  • Kansas City Cardiomyopathy Questionnaire (KCCQ)-Total Symptom Score (TSS) [ Time Frame: 28 days ]
  • Left Atrial Volume index (LAVi) [ Time Frame: 2 days ]

Central Contacts and Locations

Central contacts

Clinical Operations Director

Brian.Sontag@Corteriapharma.com

Locations

NC Heart and Vascular Research, LLC

Recruiting

Raleigh, North Carolina, United States, 27607

Ohio State University

Recruiting

Columbus, Ohio, United States, 43210

More Information

Sponsor

Corteria Pharmaceuticals

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • COR-1167
  • Hospitalised heart failure
  • WHF

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Corteria Pharmaceuticals on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.